Chronic Lymphocytic Leukemia | Specialty

FDA Grants Venetoclax Full Approval for CLL, Regardless of 17p Deletion

June 8th 2018

The FDA has granted a regular approval to venetoclax for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, with or without 17p deletion, following at least 1 prior therapy. The BCL-2 inhibitor is now also approved for use in combination with rituximab in the same patient population.

Frontline Ibrutinib/Venetoclax Combo Shows High MRD-Negative Responses for CLL

June 4th 2018

The frontline combination of ibrutinib and venetoclax demonstrated a 100% objective response rate for patients with chronic lymphocytic leukemia, with 77% of patients testing negative for minimal residual disease in the peripheral blood after 6 cycles.

Frontline Ibrutinib Plus Obinutuzumab Improves PFS in Phase III CLL Trial

May 24th 2018

Frontline treatment with the combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) improved progression-free survival compared with chlorambucil plus obinutuzumab in patients with CLL or SLL.

Expert Assesses Available Treatments in CLL

May 18th 2018

Ryan W. Jacobs, MD, discusses the use of small molecule inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Dr. Jacobs Discusses the Frontline Treatment of CLL

May 15th 2018

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the frontline treatment of patients with chronic lymphocytic leukemia.

Sorting Through the Alphabet Soup of Evolving Treatments in CLL

May 15th 2018

Experts offer their perspectives on developments in the field of chronic lymphocytic leukemia, such as novel combinations and emerging agents.

Dr. Skarbnik Discusses the Changing Landscape of CLL

May 7th 2018

Alan Skarbnik, MD, staff physician, Department of Bone Marrow Transplantation and Department of Lymphoma, John Theurer Cancer Center, discusses the changing treatment landscape of chronic lymphocytic leukemia.

Memory-Related Genes May Overcome Resistance to CAR T-Cell Therapy in CLL

May 3rd 2018

Results from a recent study may show why some patients with chronic lymphocytic leukemia are resistant to tisagenlecleucel, while potentially offering a pathway to enhance patient response.

Dr. Byrd Discusses the Prognosis of Patients With CLL

April 28th 2018

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the prognosis of patients with chronic lymphocytic leukemia.

Dr. Jacobs on the Use of Ibrutinib in High-Risk Patients With CLL

April 27th 2018

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the use of ibrutinib (Imbruvica) in high-risk patients with chronic lymphocytic leukemia (CLL).

Dr. Kay Discusses Combination Strategies in CLL

April 9th 2018

Neil E. Kay, MD, professor of medicine, Mayo Clinic, discusses combination strategies for patients with chronic lymphocytic leukemia (CLL).

FDA Grants Duvelisib Priority Review for CLL and Follicular Lymphoma

April 9th 2018

The FDA has granted a priority review to a new drug application for duvelisib for a full approval for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and an accelerated approval for the treatment of patients with relapsed/refractory follicular lymphoma.

Dr. Byrd on Challenges Facing CLL

April 6th 2018

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the challenges facing the field of chronic lymphocytic leukemia (CLL).

Expert Reviews CLL Advances Presented at ASH

April 5th 2018

Alan Skarbnik, MD, shares his insight on the latest updates in chronic lymphocytic leukemia presented at the 2017 ASH Annual Meeting.

The Evolving Treatment Landscape of CLL

March 31st 2018

Relapsed/Refractory CLL: Evaluating Other Novel Agents

March 31st 2018

Novel Approaches to Treating Relapsed/Refractory CLL

March 31st 2018

Continuing Therapy in Relapsed/Refractory CLL

March 31st 2018

Evaluating Pharmacologic Agents in Relapsed/Refractory CLL

March 31st 2018

CLL: Post-Ibrutinib or Chemoimmunotherapy Approaches

March 31st 2018